Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2025 17:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted...
January 13, 2025 07:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Provides Corporate Update and 2025 Outlook

Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA...
November 13, 2024 17:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted...
July 22, 2021 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Report Second Quarter 2021 Financial Results

SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close...
June 04, 2021 08:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced presentations including nonclinical data examining the renal protective effects of sparsentan, a high...
June 02, 2021 08:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is...
February 10, 2021 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...
January 12, 2021 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
January 11, 2021 07:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Provides Corporate Update and 2021 Outlook

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
December 01, 2020 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to...